Your session is about to expire
← Back to Search
CC-122 for Multiple Myeloma
Study Summary
This trial is to test the safety and effectiveness of a new drug for people with advanced tumors that haven't responded to other treatments. They'll also be finding out what the best dose is and how often it should be taken.
- Multiple Myeloma
- Lymphoma
- Diffuse Large B-Cell Lymphoma
- Pleiotropic Pathway Modifier
- Glioblastoma
- Central Nervous System Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 62 Patients • NCT03310619Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- If you have GBM, you don't need to have visible signs of the disease to participate in the study.You had any other type of cancer within the past 5 years, except for certain cases.You have a serious heart condition.You have other serious or uncontrolled health conditions at the same time.You have had a solid organ transplant in the past.Any health condition that could make it difficult to understand the results of the study.You have cancer that has not responded to or you cannot tolerate standard treatments. You must have measurable signs of the disease.You have cancer that has spread to your brain and it is causing symptoms, except if you have certain types of brain cancer (GBM or PCNSL).You have been diagnosed with a specific type of cancer (DLBCL-2, PCNSL, GBM-2, or Multiple Myeloma) that the study is focusing on.
- Group 1: CC-122- GBM-2
- Group 2: CC-122- DLBCL-2
- Group 3: CC-122 MM-2
- Group 4: Primary Central Nervous System Lymphoma (PCNSL)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has CC-122 been given the regulatory go-ahead by the Food and Drug Administration?
"As CC-122 is being tested in its earliest stages, the safety rating of this drug stands at a 1 due to an absence of substantial data on both efficacy and toxicity."
What is the total number of participants involved in this clinical trial?
"This clinical trial is not accomodating applicants presently. It was initially launched on September 12th 2011 and the most recent amendment to it occured on October 27th 2022. For those seeking other trials, 2905 studies related to lymphoma are actively recruiting patients as well as 5 more that involve CC-122 specifically."
In which geographical areas has this clinical trial been implemented?
"The medical research is available in 17 different sites, including Swedish Medical Center Cancer Institute Research (Seattle), Local Institution - 020 (New york) and Henry Ford Medical Center - New Center One (Detroit)."
Are there any other investigations involving CC-122 that have been conducted previously?
"The first clinical trial involving CC-122 was conducted at A.O.U. di Bologna Policlinico S.Orsola-Malpighi in 2011, subsequently being replicated 8 times and 5 more trials currently active around the globe, notably Seattle, Washington."
Is this the inaugural investigation of its kind?
"CC-122 has had a lengthy history of clinical trials with its initial study commencing in 2011, organised by Celgene. After being approved for Phase 1 drug use, it is now the subject of five distinct investigations that span eight countries and 38 cities."
Is this research endeavor currently accepting participants?
"Clinicaltrials.gov records show that this medical trial, first uploaded on September 12th 2011 and last modified on October 27th 2022, is not recruiting new patients at the moment. Fortunately, there are 2,910 other clinical trials currently in search of participants."
Share this study with friends
Copy Link
Messenger